No. |
Variant name |
Chromosome position |
Chromatin state |
Related regulatory elements |
Target genes |
Extended variants |
Associated traits |
1 |
rs1283312 |
chr2:213314899-213314900 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
2 |
rs538478719 |
chr2:213314920-213314921 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
3 |
rs547243018 |
chr2:213314925-213314926 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
4 |
rs565649512 |
chr2:213314939-213314940 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
5 |
rs527779071 |
chr2:213314944-213314945 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
6 |
rs536189593 |
chr2:213314974-213314975 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
7 |
rs550044183 |
chr2:213315017-213315018 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
8 |
rs569980139 |
chr2:213315020-213315021 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
9 |
rs6435705 |
chr2:213315099-213315100 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
10 |
rs13420607 |
chr2:213315100-213315101 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
11 |
rs188573800 |
chr2:213315138-213315139 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
12 |
rs571415593 |
chr2:213315200-213315201 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
13 |
rs541644531 |
chr2:213315240-213315241 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
14 |
rs554193980 |
chr2:213315278-213315279 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
15 |
rs553662317 |
chr2:213315303-213315304 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
16 |
rs527304105 |
chr2:213315361-213315362 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
17 |
rs575200398 |
chr2:213315393-213315394 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
18 |
rs192995167 |
chr2:213315419-213315420 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
19 |
rs140749510 |
chr2:213315463-213315464 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
20 |
rs185638904 |
chr2:213315542-213315543 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
21 |
rs571989010 |
chr2:213315545-213315546 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
22 |
rs57931477 |
chr2:213315564-213315565 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
23 |
rs377123495 |
chr2:213315565-213315566 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
24 |
rs142976602 |
chr2:213315606-213315607 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
25 |
rs534794034 |
chr2:213315656-213315657 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
26 |
rs547402436 |
chr2:213315701-213315702 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
27 |
rs190411896 |
chr2:213315783-213315784 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
28 |
rs180675867 |
chr2:213315792-213315793 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
29 |
rs111840650 |
chr2:213315801-213315802 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
30 |
rs112753493 |
chr2:213315838-213315839 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
31 |
rs565588379 |
chr2:213315839-213315840 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
32 |
rs150036405 |
chr2:213315841-213315842 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
33 |
rs551520860 |
chr2:213315844-213315845 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
34 |
rs548111753 |
chr2:213315878-213315879 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
35 |
rs569997836 |
chr2:213315897-213315898 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
36 |
rs537070540 |
chr2:213315994-213315995 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
37 |
rs16848583 |
chr2:213316034-213316035 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
38 |
rs570866148 |
chr2:213316064-213316065 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
39 |
rs183865324 |
chr2:213316099-213316100 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
40 |
rs537295789 |
chr2:213316135-213316136 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
41 |
rs557613298 |
chr2:213316154-213316155 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
42 |
rs78247957 |
chr2:213316169-213316170 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
43 |
rs535397428 |
chr2:213316212-213316213 |
Weak transcription Enhancers Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
44 |
rs575112541 |
chr2:213316213-213316214 |
Weak transcription Enhancers Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
45 |
rs115335172 |
chr2:213316217-213316218 |
Weak transcription Enhancers Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
46 |
rs561685709 |
chr2:213316236-213316237 |
Weak transcription Enhancers Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
47 |
rs369335418 |
chr2:213316298-213316299 |
Weak transcription Enhancers Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
48 |
rs188425515 |
chr2:213316306-213316307 |
Weak transcription Enhancers Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
49 |
rs73989006 |
chr2:213316320-213316321 |
Weak transcription Enhancers Active TSS
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
50 |
rs181191569 |
chr2:213316327-213316328 |
Weak transcription Enhancers Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|